However, secondary treatment of cells with the p38 inhibitor SB203580 had limited success in restoring impaired lymphocyte function and COPD-induced inflammation suppression, indicating the importance of p38-independent inflammatory mechanisms in the pathogenesis of COPD [43] (Table 2). The gene discussed is MAPK1; the disease is chronic obstructive pulmonary disease.